Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||DNMT3A mutant|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|DNMT3A mutant||acute myeloid leukemia||predicted - sensitive||Decitabine||Clinical Study - Cohort||Actionable||In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to patients with wild-type DNMT3A when treated with frontline hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649).||27418649|
|DNMT3A mutant||angioimmunoblastic T-cell lymphoma||not applicable||N/A||Guideline||Diagnostic||DNMT3A mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).||detail...|
|DNMT3A mutant||myelofibrosis||not applicable||N/A||Guideline||Prognostic||DNMT3A mutations are associated with inferior overall survival in patients with primary myelofibrosis (NCCN.org).||detail...|
|DNMT3A mutant||acute myeloid leukemia||sensitive||Pinometostat||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Pinometostat (EPZ-5676) treatment of acute myeloid leukemia cell lines and xenografts resulted in apoptosis, cell-cycle arrest, and terminal differentiation (PMID: 27335278).||27335278|
|DNMT3A mutant||acute myeloid leukemia||not applicable||N/A||Clinical Study||Prognostic||In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448).||22490330 21881046 21670448|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03365661||Phase II||ALT-803||QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML||Withdrawn|
|NCT04708054||Phase II||Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax||Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome||Not yet recruiting|